Vaxcyte, Inc. PCVX

Company Overview

Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing novel vaccines for the prevention or treatment of bacterial infectious diseases. The company operates within the biotechnology and vaccine development industries, with a strategic emphasis on improving vaccine breadth, immunogenicity, and manufacturability through proprietary conjugate vaccine technologies. Vaxcyte’s primary revenue profile remains research and development-driven, as the company has not yet commercialized products and derives funding primarily from equity financing, strategic collaborations, and investment activities disclosed in SEC filings. Its lead programs target invasive pneumococcal disease, Group A Streptococcus infections, and other serious bacterial pathogens affecting both pediatric and adult populations.

The company was founded in 2013 and is headquartered in San Carlos, California. Vaxcyte evolved from advances in synthetic chemistry and protein engineering technologies intended to improve upon traditional vaccine conjugation methods. Its strategic positioning is centered on its proprietary carrier-sparing platform and site-specific conjugation technologies designed to enable broader-spectrum vaccines with potentially enhanced immune responses and scalable manufacturing advantages compared with conventional approaches. The company’s lead asset, VAX-31, is positioned as a next-generation pneumococcal conjugate vaccine candidate intended to compete in the global adult and pediatric pneumococcal vaccine markets currently dominated by large pharmaceutical companies.